Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls

Maria Holtze, MSc; Peter Saetre, PhD; Göran Engberg, PhD; Lilly Schwieler, PhD; Thomas Werge, PhD; Ole A. Andreassen, MD, PhD; Håkan Hall, PhD; Lars Terenius, PhD; Ingrid Agartz, MD, PhD; Erik G. Jönsson, MD, PhD; Martin Schalling, MD, PhD; Sophie Erhardt, PhD

Holtze, Engberg, Schwieler, Erhardt — Department of Physiology and Pharmacology, Karolinska Institutet; Saetre, Hall, Terenius, Agartz, Jönsson — Department of Clinical Neuroscience, HUBIN Project, Karolinska Institutet and University Hospital, Stockholm, Sweden; Werge — Research Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Copenhagen University Hospital, Roskilde, Denmark; Andreassen — TOP project, Division of Psychiatry, Ullevål University Hospital & Institute of Psychiatry, University of Oslo; Agartz — Institute of Psychiatry, University of Oslo, Psykiatrisk institutt, Vinderen, and the Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway; Schalling — Department of Molecular Medicine and Surgery, Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden

Introduction

In recent years, the general view of the pathophysiology of schizophrenia (i.e., disturbances in dopamine [DA] transmission) has been expanded to also involve a glutamatergic dysfunction of the brain. Thus, clinical observations show that systemic administration of N-methyl-D-aspartate receptor antagonists (e.g., phencyclidine [PCP] and ketamine) evokes schizophrenia-like symptoms in healthy individuals and provokes symptoms in patients with schizophrenia. A hypoglutamatergic state of the brain can also be achieved by elevation of the endogenous NMDA receptor antagonist kynurenic acid (KYN A). This compound is an end-metabolite of the kynurenic pathway, and its formation indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine. Indeed, increased concentrations of KYN A have been found in the cerebrospinal fluid (CSF) and in the post-mortem brains of patients with schizophrenia. Furthermore, the glutamate deficiency theory has gained some support from genetic findings. A hypoglutamatergic state of the brain can also be achieved by elevation of the endogenous NMDA receptor antagonist kynurenic acid (KYN A). Indeed, increased concentrations of KYN A have been found in the cerebrospinal fluid (CSF) and in the post-mortem brains of patients with schizophrenia. Kynurenic acid is a metabolite of tryptophan (Fig. 1) and acts as an antagonist at the glycine coagonist site and the glutamate recognition site of the NMDA receptor. Additionally, KYN A blocks the α7* nicotinic receptor at low concentrations. Elevated levels of KYN A in the rat brain are associated with
increased midbrain DA firing\textsuperscript{14–17} and disrupted prepulse inhibition,\textsuperscript{18} a deficit that has also been observed in patients with schizophrenia.\textsuperscript{19} In this regard, KYNA has important similarities to other NMDA receptor antagonists.\textsuperscript{20,21}

Formation of KYNA indirectly depends on the activity of kynurenine 3-monooxygenase (KMO), the enzyme converting kynurenine to 3-hydroxykynurenine.\textsuperscript{22} Thus, pharmacologic intervention of this enzyme will shunt the metabolism of kynurenine to KYNA. A functional polymorphism of the gene encoding the enzyme KMO, possibly resulting in a reduction of the expression of KMO and/or its enzyme activity, may contribute to the elevated levels of KYNA in patients with schizophrenia. The KMO gene is located on chromosome 1q42 and, interestingly, several genetic analyses of families densely affected with schizophrenia and schizoaffective disorder have reported linkage to this region.\textsuperscript{23,24} Furthermore, genes in this region are suggested to affect susceptibility to these disorders.\textsuperscript{25,26} However, to our knowledge, no association between KMO polymorphisms and schizophrenia has yet been reported.\textsuperscript{27,28}

In the present study, we analyzed whether polymorphisms in the gene encoding the enzyme KMO have an impact on CSF concentrations of KYNA in a Swedish sample of patients with schizophrenia and healthy controls.

**Methods**

**Samples**

For association analysis between KMO polymorphisms and CSF concentrations of KYNA, we recruited participants with schizophrenia and healthy controls who had been previously included in a case–control study in which our group analyzed KMO polymorphisms.\textsuperscript{29} Cerebrospinal fluid concentrations of KYNA in both controls and patients with schizophrenia have previously been published.\textsuperscript{25,26}

We invited patients with schizophrenia to participate in the study. None of them was subjected to involuntary treatment. We obtained informed consent from patients and controls after providing written and verbal information about the procedure and the purpose of the study. All patients included in the study were competent to give informed consent according to the opinion of psychiatrists familiar with the patients. We recruited healthy controls among age-matched students and hospital staff members. All controls were found to be free from current signs of psychiatric morbidity or difficulties in social adjustment at the time of sampling according to an interview performed by a psychiatrist. Patients and controls included in the present study are those from whom both CSF and blood were collected. The study was approved by the ethical committees of the Karolinska Institutet.

**Genotyping**

We selected 15 KMO single nucleotide polymorphisms (SNPs) spanning 60 kb from the 5′ near gene region to intron 15 for genotyping, including at least 2 in each of the 4 haplotype blocks of the gene (Appendix 1, available at www.cma.ca /jpn), representing gene coverage of 79%.\textsuperscript{28} Genomic DNA was extracted from whole blood samples. The selected SNPs were genotyped at the SNP Technology Platform in Uppsala, Sweden (www.genotyping.se) using the Illumina BeadStation 500GX and the 1536-plex Illumina Golden Gate assay (Illumina Inc.). All SNPs were in Hardy–Weinberg equilibrium. The sample success rate was on average 99.4% for the genotyped SNPs, and the reproducibility of the genotyping was 100%, as determined from a sample of 873 broad-spectrum patients with schizophrenia and 1473 unrelated Scandinavian controls, including those enrolled in this study.\textsuperscript{29}

**Cerebrospinal fluid sampling**

We obtained CSF by lumbar puncture after participants had a minimum of 8 hours of observed bedrest and abstinence from food and smoking before sampling. For a more detailed description of the procedure, see Nilsson and colleagues\textsuperscript{8} and Holtze and colleagues.\textsuperscript{30}

**Kynurenic acid analysis**

We detected KYNA using an isocratic reversed-phase high-performance liquid chromatography (HPLC) system, including a fluorescence detector (Jasco FP-2020) with an excitation wavelength of 344 nm and an emission wavelength of 398 nm (18-nm bandwidth), as previously described.\textsuperscript{3} Samples of 25 µL were manually inserted into a Rheodyne injector (Rhonert Park), and the retention time of KYNA was about 13 minutes. The precision of the HPLC method used in the present study was routinely tested within days (intra-assay) and between days (interassay). For the determination of intra-assay precision, aliquots (n = 10) of KYNA standards at concentrations of

![Fig. 1: The kynurenine pathway.](image-url)
0.3125 nM and 5 nM were analyzed. The precision of the assay was calculated from the percent coefficient of variation (CV) of the mean, according to the equation CV (%) = (standard deviation ÷ mean) × 100. The CV (%) for 0.3125 nM was 6.44% and that for 5 nM was 1.49%. Interassay precision was calculated by analyzing aliquots of the same KYNA standard (1 nM) on 10 consecutive days. The CV (%) for interassay precision was 2.83%. We measured all samples in a single assay.

**Statistical analysis**

Cerebrospinal fluid concentrations of KYNA were treated as a quantitative trait and allele associations with KMO SNPs were tested in UNPHASED. Back length, age at the time of lumbar puncture, sex and affection state are factors that have previously been associated with CSF concentrations of KYNA. Consequently, we used these variables as confounders in the analysis. To test whether the allele association differed between individuals with schizophrenia and controls, we treated affection state as a modifier in a separate UNPHASED analysis. The number of individuals homozygous for the minor allele was typically below 4 for each SNP, and thus did not allow for meaningful genotype association tests. Correction for multiple testing was completed using a permutation test in UNPHASED (1000 permutations).

**Results**

We enrolled 50 individuals from Sweden (17 patients with schizophrenia and 33 healthy controls) in our study. The demographic and clinical characteristics of participants are summarized in Table 1. At the time of lumbar puncture, 3 of the patients were drug-free but had previously received antipsychotic drugs, whereas the remaining patients were prescribed the following neuroleptics: chlorpromazine (n = 2), perphenazine (n = 3), thioridazine (n = 2), raclopride (n = 1), cisflupenthixol (n = 1), zuclopenthixol (n = 2), a combination of clozapine and perphenazine (n = 1), a combination of haloperidol and sulpiride (n = 1), and a combination of perphenazine and thioridazine (n = 1).

We found an association between the KMO SNP rs1053230 and CSF concentrations of KYNA (likelihood ratio $\chi^2 = 10.0$, $p = 0.002$). The additive value was 1.1 (95% confidence interval 0.34–1.79), and a copy of the T-allele was associated with a 45% increase in CSF concentrations of KYNA (least square means were 1.0 nM for individuals with the CC genotype and 1.49 nM for those with the CT genotype; Fig. 2). This association was observed in both patients and controls and was significant after correction for multiple testing (adjusted $p = 0.023$, empirical 5% quantile = 0.003). Although there was a tendency toward a stronger association in affected individuals (Fig. 2), this difference was not statistically significant ($p = 0.73$ for affection state as modifier).

**Discussion**

We found that the minor allele (T) of the KMO SNP rs1053230 was strongly associated with increased CSF concentrations of KYNA. To our knowledge, this is the first study showing an association between a KMO SNP and a putative phenotype of schizophrenia (i.e., elevated levels of KYNA concentrations). This SNP is located in exon 15 and results in a shift of the amino acid sequence from arginine to cysteine. The association was evident in both healthy controls and patients with schizophrenia, and it tended to be stronger in patients.

The KMO enzyme is located at the outer membrane of the mitochondria. Although the major part of the enzyme is located inside of the membrane, the KMO polymorphism rs1053230 is situated in the part of the gene sequence coding for positions outside of the mitochondria membrane (www.predictprotein.org), likely the site for substrate interaction. Thus, an exchange of amino acids in this part of the enzyme may directly influence substrate binding, for example, affecting the hydrophathy index from −4.5 (arginine, the most hydrophilic amino acid) to 2.5 (cysteine, a moderate hydrophobic amino acid). The increased levels of KYNA, seen in individuals with the minor T allele, may thus follow a reduction of kynurenine binding to KMO. In support of this theory, it has been shown that concentrations of brain kynurenine, the precursor of KYNA, are elevated and that KMO activity is decreased.

![Fig. 2: The concentrations of kynurenic acid (KYNA) increase with the T-allele of rs1053230 (p = 0.023 after correction for multiple testing). Least square means and standard errors are given for controls and patients with schizophrenia with the CC, CT and TT genotypes, respectively, adjusting for effects of back length, age and sex.](image-url)
decreased in patients with schizophrenia. The metabolism of kynurenine would thus be shunted toward KYNA, similar to the outcome of administering pharmacologic compounds that block KMO. The availability of kynurenine is suggested to be the determinant of KYNA synthesis. One might speculate that the SNP rs1053230 is affecting the function of the KMO enzyme, as it is associated with CSF concentrations of KYNA. The functionality of this SNP is, however, not explored in the present study. An in vitro enzymatic assay, overexpressing the different KMO variants, including either the C allele or the T allele of this SNP as the only genetic difference, would have been a desirable approach to analyze functionality. However, since KMO is a mitochondria–membrane bound enzyme, estimating its activity in an artificial environment might be problematic.

Participants in the present study represent a smaller fraction of those included in the study by Nilsson and colleagues, in which CSF concentrations of KYNA were found to be significantly higher in patients than controls. Possibly, the lack of a difference in CSF concentrations of KYNA between patients and controls in the present study was related to the restricted number of samples analyzed, and the less disparate CSF concentrations of KYNA in the 2 groups might mainly be explained by higher KYNA concentrations in controls in the present analysis compared with those controls in the larger study for whom DNA was not available. Despite this limitation, it is of interest to note that the association between the KMO (rs1053230) T allele and increased KYNA concentration tended to be stronger in patients compared with controls (Fig. 2). Notably though, KMO SNPs per se do not confer major susceptibility to schizophrenia.

Synthesis of KYNA is not only affected by the activity of the enzyme KMO, but is also critically regulated by indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO), enzymes responsible for the rate-limiting step of the kynurenine pathway (Fig. 1). Notably, CSF concentrations of KYNA as well as brain IDO and TDO activity are induced during infections or immune activation, and numerous studies suggest that brain KYNA is a biologic marker of neuroinflammation. In support of an activation of the brain immune system in patients with schizophrenia, the CSF concentration of interleukin-1β, a proinflammatory cytokine, is elevated in patients with first-episode schizophrenia. Indeed, gene expression of TDO and the density of TDO-immunopositive cells are found to be elevated in the postmortem brains of patients with schizophrenia. A change in the KMO codon sequence from arginine to cysteine in combination with increased IDO and/or TDO activity may thus be responsible for the elevated KYNA concentrations seen in patients with schizophrenia.

Limitations

One limitation of the present study is the relatively small sample size for a genetic study. To reduce the influence of genetic variation, all participants were white and sampled from the same area of Sweden. Still, replication in additional samples is needed to confirm the relation. Another limitation stems from the use of antipsychotic drugs during CSF sampling among most of the patients. Generally, treatment with antipsychotic drugs should be taken into consideration as a confounding factor when evaluating biologic aberrations in the brains of patients with schizophrenia. However, chronic treatment with antipsychotics in rats has been shown to decrease brain KYNA concentrations, a finding also supported by postmortem findings in patients with schizophrenia. These findings argue against an influence of treatment in the present study. In addition, the observed association between the KMO SNP rs1053230 and KYNA concentrations was similar among the larger group of drug-free healthy participants.

Conclusion

The present findings indicate that increased levels of CSF concentrations of KYNA, as previously reported in patients with schizophrenia, are influenced by a nonsynonymous missense polymorphism in KMO.

Acknowledgements: We thank patients and controls for their participation and express our gratitude toward health professionals who facilitated our work. We thank Frank Dudbridge for advice on UNPHASED, and Agneta Gunnar, Alexandra Tylec, Monica Hellberg and Kjerstin Lind for technical assistance. We also thank Kristina Larsson, Per Lundmark, Tomas Axellson and Ann-Christine Syvänen at the SNP Technology Platform for performing the genotyping. The SNP Technology Platform is supported by Uppsala University, Uppsala University Hospital, and by the Knut and Alice Wallenberg Foundation.

Funding: This study was financed by grants from the Hällstens Forskningsstiftelse, Swedish Brain Foundation, Svenska Läkaresällskapet, Karolinska Institutet, Torsten och Ragnar Söderbergs stiftelse, Swedish Medical Research Council, Söderström-Königska stiftelsen, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, Copenhagen Hospital Corporation Research Fund, the Danish National Psychiatric Research Foundation, the Danish Agency for Science, Technology and Innovation (Centre for Pharmacogenetics) to T. Werger, the Research Council of Norway (147787, 16713), the Eastern Norway Health Authority (Helse Øst RHF 123/2004), Umeå University Hospital, and University of Oslo to the TOP study (O.A. Andreassen), the Swedish Research Council (No. 2009-042 and 2009-07032, [S. Erhardt]), K2009-62X-07484-24-3 (G. Engberg), K2007-62X-15077-04-1 (Ingrid Agartz), K2007-62X-15078-04-3 (E.G. Jönsson), K2008-62P-20597-01-3 (E.G. Jönsson), 10909 [M. Schalling]), the Knut and Alice Wallenberg Foundation (L. Terniö) and the HUBIN project. The funding sources had no further role in the study design, in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Competing interests: None declared for M. Holtze and P. Saetre, L. Schwieler, H. Hall, M. Schalling and S. Erhardt. As above for G. Engberg, T. Werger, O.A. Andreassen, L. Terniö, I. Agartz and E.G. Jönsson. T. Werger also declares having received consultancy and lecture fees from Lundbeck A/S.

Contributors: M. Holtze coordinated the preparation of the manuscript and wrote the initial draft. P. Saetre performed and drafted the statistical analyses. G. Engberg participated in the study design and supervised the KYNA analyses. L. Schwieler, T. Werger and O.A. Andreassen participated in the study design and performed the KYNA analyses. H. Hall, L. Terniö and I. Agartz participated in the study design and contributed to data collection. E.G. Jönsson participated in the study design, clinical characterization and contributed to data collection.

Contribution Information: This study was financed by grants from the Hällstens Forskningsstiftelse, Swedish Brain Foundation, Svenska Läkaresällskapet, Karolinska Institutet, Torsten och Ragnar Söderbergs stiftelse, Swedish Medical Research Council, Söderström-Königska stiftelsen, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, Copenhagen Hospital Corporation Research Fund, the Danish National Psychiatric Research Foundation, the Danish Agency for Science, Technology and Innovation (Centre for Pharmacogenetics) to T. Werger, the Research Council of Norway (147787, 16713), the Eastern Norway Health Authority (Helse Øst RHF 123/2004), Umeå University Hospital, and University of Oslo to the TOP study (O.A. Andreassen), the Swedish Research Council (No. 2009-042 and 2009-07032, [S. Erhardt]), K2009-62X-07484-24-3 (G. Engberg), K2007-62X-15077-04-1 (Ingrid Agartz), K2007-62X-15078-04-3 (E.G. Jönsson), K2008-62P-20597-01-3 (E.G. Jönsson), 10909 [M. Schalling]), the Knut and Alice Wallenberg Foundation (L. Terniö) and the HUBIN project. The funding sources had no further role in the study design, in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Competing interests: None declared for M. Holtze and P. Saetre, L. Schwieler, H. Hall, M. Schalling and S. Erhardt. As above for G. Engberg, T. Werger, O.A. Andreassen, L. Terniö, I. Agartz and E.G. Jönsson. T. Werger also declares having received consultancy and lecture fees from Lundbeck A/S.

Contributors: M. Holtze coordinated the preparation of the manuscript and wrote the initial draft. P. Saetre performed and drafted the statistical analyses. G. Engberg participated in the study design and supervised the KYNA analyses. L. Schwieler, T. Werger and O.A. Andreassen participated in the study design and performed the KYNA analyses. H. Hall, L. Terniö and I. Agartz participated in the study design and contributed to data collection. E.G. Jönsson participated in the study design, clinical characterization and contributed to data collection.

56 J Psychiatry Neurosci 2012;37(1)
References


34. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenic and kynurenine acid in the CSF of patients with schizophrenia. *Schizophr Bull* 2010 Aug. 10. [Epub ahead of print]


